Stockscreener 앱 받기
71.71
2.22%
-1.63
전일 마감가:
$73.34
열려 있는:
$73.34
하루 거래량:
2.04M
Relative Volume:
0.95
시가총액:
$8.43B
수익:
$947.36M
순이익/손실:
$392.47M
주가수익비율:
23.75
EPS:
3.02
순현금흐름:
$392.71M
1주 성능:
+3.60%
1개월 성능:
+5.92%
6개월 성능:
+19.36%
1년 성능:
+27.10%
1일 변동 폭
$71.30
$74.48
1주일 범위
$68.85
$74.48
52주 변동 폭
$47.50
$79.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
명칭
Halozyme Therapeutics Inc
전화
(858) 794-8889
주소
12390 EL CAMINO REAL, SAN DIEGO, CA
HALO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
71.71 | 8.62B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-10-14 | 업그레이드 | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-05-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 다운그레이드 | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-06-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 개시 | TD Cowen | Outperform |
| 2023-07-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-24 | 개시 | H.C. Wainwright | Buy |
| 2023-05-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Berenberg | Buy |
| 2023-03-16 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 재개 | Morgan Stanley | Overweight |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 개시 | Evercore ISI | Outperform |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 재확인 | The Benchmark Company | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | The Benchmark Company | Buy |
| 2020-02-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Buy |
| 2019-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 재개 | Piper Jaffray | Neutral |
| 2018-05-11 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-16 | 재확인 | Piper Jaffray | Overweight |
| 2017-01-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-11-18 | 개시 | Citigroup | Buy |
| 2015-09-22 | 개시 | Barclays | Overweight |
| 2015-06-22 | 재확인 | JP Morgan | Overweight |
| 2015-03-03 | 재확인 | UBS | Buy |
| 2015-02-18 | 재확인 | MLV & Co | Buy |
| 2015-01-08 | 재확인 | MLV & Co | Buy |
모두보기
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
2 Under-the-Radar Biotech Stocks Set to Boom in 2026 - AOL.com
What Halozyme Therapeutics (HALO)'s Upgraded Revenue Outlook and ENHANZE Acquisitions Strategy Means For Shareholders - Yahoo Finance
AlphaQuest LLC Acquires 34,011 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Raised to Strong-Buy at Wall Street Zen - MarketBeat
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Setup Watch: Is Halozyme Therapeutics Inc forming a breakout patternDip Buying & AI Optimized Trading Strategy Guides - baoquankhu1.vn
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
Q4 EPS Forecast for Halozyme Therapeutics Lifted by Analyst - MarketBeat
Great Lakes Advisors LLC Sells 14,747 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
H.C. Wainwright Sees Strength in Halozyme Therapeutics' ENHANZE Platform, Reiterates Buy Rating - Finviz
H.C. Wainwright Sees Strength in Halozyme Therapeutics’ ENHANZE Platform, Reiterates Buy Rating - Yahoo Finance
Halozyme stock price target maintained at $58 by Goldman Sachs - Investing.com Canada
HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance - Yahoo Finance
Halozyme Acquires Surf Bio for up to $400M - Contract Pharma
H.C. Wainwright reiterates Buy rating on Halozyme stock, maintains $90 price target - Investing.com Canada
Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2026 Earnings Guidance - MarketBeat
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Growth and Technical Setup - Chartmill
Federated Hermes Inc. Has $106.40 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Is Halozyme Therapeutics (HALO) Offering Value After Strong Multi‑Year Share Price Gains - Yahoo Finance
Halozyme Therapeutics Projects Sustained Growth Well Into 2040 - Benzinga
Risk Off: What is Halozyme Therapeutics Incs market position2025 Breakouts & Breakdowns & Consistent Return Strategy Ideas - baoquankhu1.vn
Halozyme Deepens ENHANZE Reach With Surf Bio Deal And Takeda Tie-Up - Yahoo Finance
Halozyme Therapeutics Raises 2026 Guidance After Hypercon, Surf Bio Deals Extend Platform Into 2040s - MarketBeat
Halozyme buys a biotech startup; Cytokinetics launches heart drug - BioPharma Dive
Halozyme Therapeutics Raises 2025, 2026 Outlooks - marketscreener.com
(HALO) Halozyme Therapeutics Expects Full Year 2026 Non-GAAP EPS Range $7.75$8.25, vs. FactSet Est of $8.24 - marketscreener.com
Halozyme Therapeutics, Inc. acquired Surf Bio, Inc. for $400 million. - marketscreener.com
Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance - The Malaysian Reserve
Halozyme (HALO) Projects Strong Revenue Growth for FY26 - GuruFocus
Halozyme Therapeutics, Inc. Raises Earnings Guidance for the Year 2026 - marketscreener.com
Halozyme Therapeutics, Inc. Updates Earnings Guidance for the Year Ended December 31, 2025 - marketscreener.com
Enhanced Guidance Boosts Halozyme's (HALO) Growth Prospects - GuruFocus
Halozyme Lifts 2025 Revenue Outlook, FY26 Guidance - Nasdaq
Halozyme raises 2025 revenue estimates, raises 2026 and multi-year financial guidance - marketscreener.com
Hussman Strategic Advisors Inc. Reduces Stock Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
EFG Asset Management North America Corp. Has $5.83 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
How Takeda ENHANZE License Deal in IBD Will Impact Halozyme Therapeutics (HALO) Investors - Sahm
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Exploring a 11.42% Potential Upside with Strong Revenue Growth - DirectorsTalk Interviews
Biotech Recovery: Halozyme and Catalyst Stocks Surge Amid Strong Growth - Intellectia AI
Halozyme and Catalyst Report Double-Digit Revenue Growth, Strong Outlook - Intellectia AI
Value Recap: Will Halozyme Therapeutics Inc benefit from rate cutsJuly 2025 Earnings & Free Community Supported Trade Ideas - baoquankhu1.vn
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
TD Cowen Notes Shifting Positive Sentiment for Halozyme (HALO) Ahead of Q4 Earnings, 2026 Guidance - Insider Monkey
Can Halozyme Therapeutics Inc benefit from deglobalizationWeekly Market Report & Target Return Focused Picks - baoquankhu1.vn
How (HALO) Movements Inform Risk Allocation Models - Stock Traders Daily
14 Best Mid-Cap Growth Stocks to Buy Right Now - Insider Monkey
Reframing The Narrative For Halozyme Therapeutics (HALO) After The Latest Analyst Price Target - Yahoo Finance
Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update - The Malaysian Reserve
Assessing Halozyme Therapeutics (HALO) Valuation After Recent Share Price Consolidation - Yahoo Finance
Halozyme (HALO) Boosted by ENHANZE Launches and Analyst Upgrade - Insider Monkey
Skye Bioscience shares rise on Halozyme partnership to advance obesity treatment - MSN
Halozyme Therapeutics Inc (HALO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.27%
자본화:
|
볼륨(24시간):